The potential role of aging processes in AD cognitive impairment raises the possibility that candidate AD therapies are more likely to be effective if they directly address age-related degeneration along with AD-linked mechanisms, such as those involving amyloid and tau. The gene discussed is MAPT; the disease is Alzheimer disease.